Small Extravasation Prospective: None The subsequent desk lists adverse outcomes that occurred in ≥ 5% of sufferers in a very section III trial comparing carfilzomib and dexamethasone therapy (2 times weekly dosing) vs . bortezomib and dexamethasone therapy. Significant adverse events from other studies or article-marketing and advertising could also https://davida703nty1.tdlwiki.com/user